Royalty Pharma plc
RPRXRoyalty Pharma is a private equity investor firm founded in 1996. It purchases the rights to royalties on future drug sales. It claims to own partial rights to 7 of the top 30 selling drugs in the United States.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
valacyclovir | Phase 2 | HIV Infections | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Royalty Pharma plc's drug pipeline?→
CatalystAlert tracks 1 drug candidate in Royalty Pharma plc's (RPRX) pipeline across Phase 2. Its lead program is valacyclovir (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Royalty Pharma plc's next FDA catalyst?→
Royalty Pharma plc's (RPRX) next tracked catalyst is a Earnings expected November 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RPRX biotech catalysts?→
Add RPRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Royalty Pharma plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.